NCT03244592 is a Phase 1, PHASE2 clinical trial of Minocycline in Alcohol Use Disorder, sponsored by University of California, Los Angeles.

Who is sponsoring NCT03244592?

NCT03244592 is sponsored by University of California, Los Angeles.

What drugs are being tested in NCT03244592?

Interventions in NCT03244592: Minocycline, Sugar pill.

What condition does NCT03244592 study?

NCT03244592 studies Alcohol Use Disorder, Inflammation, Neurocognitive Dysfunction, Craving, Alcohol Drinking.

Is NCT03244592 still recruiting?

NCT03244592 is currently withdrawn. Last updated 24 January 2019.

Last reviewed 2019-01-24 · How we verify

NCT03244592

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Minocycline for Alcohol Use Disorder

Withdrawn Phase 1, PHASE2 Last updated 24 January 2019

What this trial tests

Phase 1, PHASE2 trial testing Minocycline in Alcohol Use Disorder. Withdrawn.

Timeline

15 January 2018

Primary endpoint
1 March 2018

1 March 2018

Quick facts

Lead sponsor	University of California, Los Angeles
Phase	Phase 1, PHASE2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Start date	15 January 2018
Primary completion	1 March 2018
Estimated completion	1 March 2018

Drugs / interventions tested

Minocycline (MINOCYCLINE) — full drug profile →
Sugar pill

Conditions studied

Alcohol Use Disorder — all drugs for Alcohol Use Disorder →
Inflammation — all drugs for Inflammation →
Neurocognitive Dysfunction — all drugs for Neurocognitive Dysfunction →
Craving — all drugs for Craving →

Sponsor

University of California, Los Angeles

Who can join

Adults 21 to 55, any sex, with Alcohol Use Disorder or Inflammation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Neuroimmune signaling in alcohol use disorder.
Erickson EK, Grantham EK, Warden AS, Harris RA. · · 2019 · cited 189× · PMID 30590091 · DOI 10.1016/j.pbb.2018.12.007
Neuroinflammation in addiction: A review of neuroimaging studies and potential immunotherapies.
Kohno M, Link J, Dennis LE, McCready H, et al · · 2019 · cited 138× · PMID 30695700 · DOI 10.1016/j.pbb.2019.01.007
Promising immunomodulators for management of substance and alcohol use disorders.
Acuña AM, Park C, Leyrer-Jackson JM, Olive MF. · · 2024 · cited 5× · PMID 38803314 · DOI 10.1080/14656566.2024.2360653
Therapeutic targeting of neuroinflammation in methamphetamine use disorder.
Jeffery N, Mock PY, Yang K, Tham CL, et al · · 2025 · cited 3× · PMID 39727147 · DOI 10.1080/17568919.2024.2447226

Verify or expand the search:

Other trials of Minocycline

Trials testing the same drug.

NCT05605366 — Minocycline In Neurocognitive Outcomes - Sickle Cell Disease · Phase 1 · not yet recruiting
NCT07305896 — Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage · NA · not yet recruiting
NCT07068607 — Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradicatio · Phase 4 · recruiting
NCT06523764 — Efficacy and Safety of Tegoprazan and Minocycline Dual Therapy for Helicobacter Pylori Initial Treatment · Phase 4 · active not recruiting
NCT06120140 — Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small · Phase 2 · recruiting

Other recruiting trials for Alcohol Use Disorder

Currently open trials in the same condition.

NCT06860607 — Environment and Alcohol: A Pilot Study · Phase 1 · recruiting
NCT07325266 — Human Laboratory Study of Apremilast for Alcohol Use Disorder · Phase 2 · recruiting
NCT07046819 — Tirzepatide in MetALD · Phase 2 · recruiting
NCT07279558 — Cannabidiol and Alcohol Use Disorder Phenotypes · Phase 2 · recruiting
NCT07056894 — Effects of Action-Based Cognitive Remediation on Substance Misuse in Early Phase Psychosis · NA · recruiting

Other University of California, Los Angeles trials

Trials by the same sponsor.

NCT04846517 — rTMS for Aneroxia Nervosa in Youth · NA · not yet recruiting
NCT06701760 — Sodium Lactate in Severe TBI · Phase 2 · not yet recruiting
NCT04996667 — Effect of iNO in Patients With Submassive and Massive PE · Phase 2 · withdrawn
NCT05067387 — Evaluation of Oral THC and CBD in Men and Women · Phase 1 · not yet recruiting
NCT07534696 — Evaluation of Non-Invasive Pelvic Floor Neuromuscular Stimulation for Urinary Incontinence After Prostatectomy · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03244592 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of California, Los Angeles
Last refreshed: 24 January 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03244592.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing